X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with ALEMBIC PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs ALEMBIC PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD ALEMBIC PHARMA BIOCON LTD/
ALEMBIC PHARMA
 
P/E (TTM) x 75.8 29.2 259.8% View Chart
P/BV x 7.1 6.7 107.1% View Chart
Dividend Yield % 0.2 0.7 24.6%  

Financials

 BIOCON LTD   ALEMBIC PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
ALEMBIC PHARMA
Mar-16
BIOCON LTD/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs1,162792 146.8%   
Low Rs483443 108.9%   
Sales per share (Unadj.) Rs194.6167.0 116.5%  
Earnings per share (Unadj.) Rs34.438.2 90.2%  
Cash flow per share (Unadj.) Rs48.342.0 114.9%  
Dividends per share (Unadj.) Rs1.004.00 25.0%  
Dividend yield (eoy) %0.10.6 18.8%  
Book value per share (Unadj.) Rs241.984.9 284.9%  
Shares outstanding (eoy) m200.00188.52 106.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.23.7 114.3%   
Avg P/E ratio x23.916.2 147.7%  
P/CF ratio (eoy) x17.014.7 115.9%  
Price / Book Value ratio x3.47.3 46.7%  
Dividend payout %2.910.5 27.7%   
Avg Mkt Cap Rs m164,440116,383 141.3%   
No. of employees `0009.2NA-   
Total wages/salary Rs m7,4704,214 177.3%   
Avg. sales/employee Rs Th4,213.9NM-  
Avg. wages/employee Rs Th809.0NM-  
Avg. net profit/employee Rs Th745.2NM-  
INCOME DATA
Net Sales Rs m38,91131,487 123.6%  
Other income Rs m1,57155 2,851.2%   
Total revenues Rs m40,48231,542 128.3%   
Gross profit Rs m9,79510,060 97.4%  
Depreciation Rs m2,772722 383.9%   
Interest Rs m26037 706.5%   
Profit before tax Rs m8,3349,356 89.1%   
Minority Interest Rs m1630-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6162,160 74.8%   
Profit after tax Rs m6,8817,194 95.6%  
Gross profit margin %25.231.9 78.8%  
Effective tax rate %19.423.1 84.0%   
Net profit margin %17.722.8 77.4%  
BALANCE SHEET DATA
Current assets Rs m40,47715,066 268.7%   
Current liabilities Rs m16,7837,674 218.7%   
Net working cap to sales %60.923.5 259.4%  
Current ratio x2.42.0 122.9%  
Inventory Days Days6067 89.0%  
Debtors Days Days8341 203.9%  
Net fixed assets Rs m45,0738,237 547.2%   
Share capital Rs m1,000377 265.3%   
"Free" reserves Rs m47,37715,416 307.3%   
Net worth Rs m48,37716,005 302.3%   
Long term debt Rs m21,0820-   
Total assets Rs m93,94224,594 382.0%  
Interest coverage x33.1255.2 13.0%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.41.3 32.4%   
Return on assets %7.629.4 25.9%  
Return on equity %14.244.9 31.6%  
Return on capital %12.658.7 21.5%  
Exports to sales %055.7 0.0%   
Imports to sales %010.4 0.0%   
Exports (fob) Rs mNA17,551 0.0%   
Imports (cif) Rs mNA3,283 0.0%   
Fx inflow Rs m12,98817,811 72.9%   
Fx outflow Rs m7,8995,318 148.5%   
Net fx Rs m5,08912,493 40.7%   
CASH FLOW
From Operations Rs m6,4009,304 68.8%  
From Investments Rs m-4,985-3,105 160.6%  
From Financial Activity Rs m-1,775-1,959 90.6%  
Net Cashflow Rs m-4734,240 -11.2%  

Share Holding

Indian Promoters % 40.4 74.1 54.5%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 2.9 289.7%  
FIIs % 10.7 9.1 117.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 13.9 143.2%  
Shareholders   109,995 49,328 223.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   TORRENT PHARMA  NATCO PHARMA  ELDER PHARMA  PFIZER  ALKEM LABORATORIES  

Compare BIOCON LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; PSU & Healthcare Stocks Top Losers(09:30 am)

Asian equities are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1.20% while the Hang Seng is up 0.61%. The Shanghai Composite is trading up by 0.45%.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 20, 2018 11:57 AM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS